Recommendations on tuberculosis and treatment of inflammatory bowel disease with infliximab. 2006 Update;Recomendaciones sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab. Actualización 2006

Gastroenterologia y Hepatologia

Volumn 29, Issue 2, 2006, Pages 81-84

  Lopez San Roman A ^a   Obrador, A ^b   Fortun J ^a   Munoz P ^c   Gassull, M A ^d  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; INFLIXIMAB; ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ENTERITIS; HUMAN; LATENT VIRUS INFECTION; MYCOBACTERIUM TUBERCULOSIS; REVIEW; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 33644548397     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13083915     Document Type: Article

References (20)

1. Doménech E, Esteve-Comas M, Gomollón F, Hinojosa J, Obrador A, Panes J, Gassull MA; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). Recomendaciones para el uso de infliximab (Remicade®) en la enfermedad de Crohn. GETECCU 2001. Gastroenterol Hepatol. 2002;25:162-9.
2. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-104.
3. Obrador A, López San Román A, Muñoz P, Fortún J, Gassull MA; Grupo Español de Trabajo de Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). Guía de consenso sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab. Gastroenterol Hepatol. 2003;26:29-33.
4. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004;50:372-9.
5. Núñez Martínez O, Ripoll Noiseux C, Carneros Martín JA, González Lara V. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment. Am J Gastroenterol. 2001;96:1665-6.
6. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122-7.
7. Salmon D; GTI-AFSSAPS. Groupe Tuberculose et infliximab. Agence Francaise de Securite Sanitaire de Produits de Sante. Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine. 2002;69:170-2.
8. Mazurek GH, Villarino ME. Guidelines for using the Quantiferon®-TB test for diagnosing latent Mycobacterium tuberculosis Infection. MMWR Morb Mort tal Wkly Rep. 2003;52(RR02):15-8.
9. Ewer K, Deeks J, Álvarez L, Bryant G, Waller S, Andersen P, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet. 2003;361:1168-73.
10. Jasmer RM, Nahid P, Hopewell PC. Latent tuberculosis infection. N Engl J Med. 2002;347:1860-6.
11. Sánchez-Arcilla I, Vílchez JM, García de la Torre M, Fernández X, Noguerado A. Infección tuberculosa latente en población indigente. Comparación de dos pautas terapéuticas. Med Clin (Barc). 2004;122:57-9.
12. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med. 2002;137:640-7.
13. Van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, Van der Spoel JI, Wester JP, Zandstra DF. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med. 2003;29:2327-9.
14. Parra Ruiz J, Ortego Centeno N, Raya Álvarez E. Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. J Rheumatol. 2003;30:1657-8.
15. Taylor JC, Orkin R, Lanham J. Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy. Rheumatology (Oxford). 2003;42:901-2.
16. García Vidal C, Rodríguez S, Martínez Lacasa J, Salavert M, Vidal R, Rodríguez Carballeira M, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis. 2005;40:756-9.
17. Vlachaki E, Psathakis K, Tsintiris K, Iliopoulos A. Delayed response to anti-tuberculosis treatment in a patient on infliximab. Respir Med. 2005;99:648-52.
18. De Rosa FG, Craven DE. Treatment of latent tuberculosis infection. N Engl J Med. 2003;348:1292-3.
19. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-9.
20. Sands BE, Anderson FH, Bernstein CN, Che WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.